Wang Chengyun, Zhu Xiangyu, Xia Lei, Xie Peng, Tian Xiangyang, Shang Jin, Han Qiu
Department of Neurology, Huai'an First People's Hospital, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, No. 1 Huanghe West Road, Huai'an, 223000, Jiangsu, China.
ICU, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, 223000, Jiangsu, China.
Acta Neurol Belg. 2022 Feb;122(1):43-49. doi: 10.1007/s13760-021-01601-9. Epub 2021 Jan 29.
This study aimed at assessing mental health in patients with hemifacial spasm (HFS) and determined the effect of botulinum toxin type A (BTX-A) on psychological distress in patients with HFS.
Ninety-five HFS patients and 95 age- and sex-matched healthy controls were enrolled. Symptom checklist-90 (SCL-90) scores were used to measure psychological distress in HFS patients and healthy controls. The mental health status of HFS patients was also evaluated by SCL-90, before and after the injection of BTX-A. Moreover, for those patients with abnormal mental health, efficacy outcomes after treatment with BTX-A were compared with a propensity score-matched historical cohort without BTX-A treatment.
The mean scores for interpersonal sensitivity, phobia, anxiety, depression, and somatization were significantly higher among HFS patients than healthy people (P < 0.05). There was no significant difference between female patients and male patients in HFS group (P > 0.05). There were significant improvements in somatization, interpersonal sensitivity, depression, anxiety, and phobia scores before and after treatment (P < 0.05). At 2 months, more patients experienced an improvement in psychological distress in the BTX-A group (61.29% versus 38.71%; P = 0.03).
Patients with HFS are often accompanied by somatization, interpersonal sensitivity, depression, anxiety, and phobia. Our findings suggest that BTX-A can improve these symptoms. However, further well-designed prospective studies are warranted to validate our findings.
本研究旨在评估面肌痉挛（HFS）患者的心理健康状况，并确定A型肉毒杆菌毒素（BTX-A）对HFS患者心理困扰的影响。
纳入95例HFS患者和95例年龄及性别匹配的健康对照者。采用症状自评量表90（SCL-90）评分来测量HFS患者和健康对照者的心理困扰程度。在注射BTX-A前后，也通过SCL-90对HFS患者的心理健康状况进行评估。此外，对于心理健康异常的患者，将BTX-A治疗后的疗效结果与未接受BTX-A治疗的倾向评分匹配历史队列进行比较。
HFS患者在人际敏感、恐惧、焦虑、抑郁和躯体化方面的平均得分显著高于健康人群（P < 0.05）。HFS组中女性患者和男性患者之间无显著差异（P > 0.05）。治疗前后躯体化、人际敏感、抑郁、焦虑和恐惧评分有显著改善（P < 0.05）。在2个月时，BTX-A组更多患者的心理困扰得到改善（61.29%对38.71%；P = 0.03）。
HFS患者常伴有躯体化、人际敏感、抑郁、焦虑和恐惧。我们的研究结果表明BTX-A可以改善这些症状。然而，需要进一步设计良好的前瞻性研究来验证我们的发现。
